Table 1. Accrual of participants by induction dose and ACTG sites.
| Site | 1200mg FCZ* | 1600mg FCZ* | 2000mg FCZ* | AMB ** | Overall (%) |
|---|---|---|---|---|---|
| Los Angeles,USA: USC | 1 | 0 | 2 | 1 | 4 (2.4) |
| Johannesburg, South Africa: Wits Health Consortium | 0 | 2 | 1 | 1 | 4 (2.4) |
| Durban, South Africa: Enhancing Care Foundation, Durban University of Technology | 1 | 6 | 5 | 10 | 22 (13.1) |
| Lima, Peru: IMPACTA | 0 | 4 | 1 | 1 | 6 (3.6) |
| Kampala, Uganda: Joint Clinical Research Center | 0 | 16 | 24 | 17 | 57 (33.9) |
| Kericho, Kenya: Walter Reed Project | 4 | 4 | 6 | 2 | 16 (9.5) |
| Eldoret, Kenya: AMPATH at MOI University | 4 | 9 | 7 | 6 | 26 (15.5) |
| Harare,Zimbabwe:UZ/UCSF HIV Prevention Trials Unit | 2 | 8 | 2 | 6 | 18 (10.7) |
| Pune, India: BJMC | 5 | 1 | 0 | 3 | 9 (5.4) |
| Chiang Mai, Thailand: Chiang Mai University | 5 | 0 | 0 | 1 | 6 (3.6) |
| TOTAL | 22 | 50 | 48 | 48 | 168 (100) |
*Induction dose of fluconazole
**amphotericin B